Information Journal Paper
APA:
Copy. (2019). Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. LANCET NEUROLOGY, 18(11), 1021-1033. SID. https://sid.ir/paper/658685/en
Vancouver:
Copy. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. LANCET NEUROLOGY[Internet]. 2019;18(11):1021-1033. Available from: https://sid.ir/paper/658685/en
IEEE:
Copy, “Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial,” LANCET NEUROLOGY, vol. 18, no. 11, pp. 1021–1033, 2019, [Online]. Available: https://sid.ir/paper/658685/en